Aggressive Patents Should Have Senior Management Support, Pfizer Attorney Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Management should "buy-in" before controversial patents that could delay generic entry are listed, Pfizer Senior Patent Counsel Pokras says. Pokras suggests that some people, including state prosecutors, would not see the "connection" between a patent on a metered dose device and the drug product.
You may also be interested in...
Pfizer Under Investigation By New York AG Spitzer
Pfizer is under investigation by the New York State Attorney General for possible off-label promotion
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles